1. Home
  2. CIVB vs DCTH Comparison

CIVB vs DCTH Comparison

Compare CIVB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civista Bancshares Inc.

CIVB

Civista Bancshares Inc.

N/A

Current Price

$27.40

Market Cap

571.6M

Sector

Finance

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.60

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CIVB
DCTH
Founded
1884
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.6M
578.4M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
CIVB
DCTH
Price
$27.40
$16.60
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$26.60
$22.00
AVG Volume (30 Days)
143.7K
701.8K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
2.90%
N/A
EPS Growth
31.34
107.53
EPS
1.41
0.04
Revenue
$19,023,000.00
N/A
Revenue This Year
$14.88
$24.54
Revenue Next Year
$5.99
$33.15
P/E Ratio
$19.44
$414.50
Revenue Growth
N/A
N/A
52 Week Low
$19.84
$8.12
52 Week High
$29.97
$17.42

Technical Indicators

Market Signals
Indicator
CIVB
DCTH
Relative Strength Index (RSI) 45.65 60.59
Support Level $27.00 $9.98
Resistance Level $29.31 $17.42
Average True Range (ATR) 0.53 0.43
MACD -0.05 -0.18
Stochastic Oscillator 50.00 39.11

Price Performance

Historical Comparison
CIVB
DCTH

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: